Patients will complete several self-questionnaires on living conditions and quality of life. They will also perform a cardiac, pulmonary, auditory and biological assessment

Healthy volunteers will complete several self-questionnaires on living conditions and quality of life.

Germ Cell Tumor

Sex Cord Stromal Tumor

Malignant Non-epithelial Ovarian Tumors

Patients will complete self-questionnaires of living conditions and quality of life (MFI-20, FACT-G/FACT-O, FACT/COG-NTX, FACT-Cog, HADS, Insomnia Severity Index , International Physical Activity Questionnaire)

Self-questionnaires of living conditions and quality of life

Patients will perform :
Cardiac assesments (ECG, Carotid and humeral Doppler ultrasound, Trans-thoracic echocardiography 2D and 3D)
Pulmonary and auditory assesment ( Respiratory Functional Exploration, Tonal audiogram)
Blood tests

Cardiac, pulmonary, auditory and biological assessment

Centre Paul Papin

CHU Besançon Jean MINJOZ

Institut Bergonié

CH Fleyriat

Centre François Baclesse

Centre Jean Perrin

Centre Léon Berard

Institut Paoli Calmettes

Centre Catherine de Sienne

Institut de Cancérologie de l'Ouest

GH Cochin Broca Hôtel-Dieu

HEGP

Hôpital Diaconesses-Croix St Simon

Institut Curie,

Institut Gustave Roussy

CHU Poitiers

Institut Jean Godinot

Institut Rennais de Cancérologie

CHRU Stasbourg Hôpital Civil

Living After a Rare Cancer of the Ovary: Chronic Fatigue, Quality of Life and Late Effects of Chemotherapy

Centre Francois Baclesse

ARCAGY/ GINECO GROUP

Patients and healthy volunteers will complete several self-questionnaires on living conditions and quality of life. Patients will also perform a cardiac, pulmonary, auditory and biological assessment

Patients treated with chemotherapy >20 years ago

Patients treated with radiotherapy >20 years ago

Patients treated with only orchidectomy >20 years ago

Testicular Cancer

University Medical Center Groningen

Health Status and Burden of Late Effects in Very Long-term Testicular Cancer Survivors (STANDBY-study)

J.A. Gietema

Principal investigator

Testicular Neoplasms

Webpage with basic information on the cohort study and link to the electronic case report form (eCRF) portal

Kantonsspital St.Gallen; Onkologie/Haematologie

Swiss Austrian German Testicular Cancer Cohort Study - SAG TCCS

Diagnostic performance and the clinical impact of a variety of tests, including conventional radiographs, computed tomographies (CT), abdominal ultrasound, serum tumour markers (AFP, beta-HCG and LDH) and clinical signs and symptoms aimed at early detection of relapse after curative therapy with documented complete remission.

Dr. med. Christian Rothermundt

Dr. med.

German Testicular Cancer Study Group

Seminoma

Stage IIA: 1 infusion Carboplatin AUC7 followed by 15 x 2 Gy involved node radiotherapy Stage IIB: 1 infusion Carboplatin AUC7 followed by 18 x 2 Gy involved node radiotherapy

Carboplatin

Involved node RT

Aachen Universitätsklinik

Berlin Universitätsklinik Charité

Berlin Vivantes - Urban

Berlin Vivantes - Neukölln

Universitaetsklinikum Düsseldorf

Klinik Essen-Mitte

Hamburg Universitätsklinikum - Eppendorf

Krefeld Maria-Hilf Krankenhaus

Universitätsklinikum Köln

Klinikum Harlaching

Universitätsklinikum Tübingen

Universitätsklinikum Ulm

Kantonspital Aarau

Kantonsspital Baden

Universitaetsspital-Basel

Istituto Oncologico della Svizzera Italiana (IOSI)

Inselspital Bern

Spitalzentrum Biel

Kantonsspital Graubuenden

Centre Hospitalier Universitaire Vaudois CHUV

Kantonsspital Olten

Hopital de Sion

Kantonsspital - St. Gallen

Regionalspital Thun

Kantonsspital Winterthur

Therapy De-escalation in Seminoma Stage IIA/B

Carboplatin Chemotherapy and Involved Node Radiotherapy in Stage IIA/B Seminoma

PFS is defined as the time from registration until one of the following events occurs:
PD or relapse, defined as progression according to the modified trial-specific version of RECIST 1.1 or a rising level of the tumor marker beta-hCG over the ULN (value must be confirmed by a second measurement). Presence of non-seminoma germ cell tumor has to be excluded in the latter case.
Death from any cause.

AEs are collected from inclusion until 30 days after the end of treatment

AEs will be collected from 30 days after the end of treatment until the end of the follow-up phase

from registration until documented progressive disease, relapse or death due to tumor.

from registration to the date of death from any cause

from registration to the date of death due to seminoma

from registration to the date of failure of PFS

from first localization where recurrent tumor disease is detected

testicular neoplasms/fatigue

Living After a Rare Cancer of the Ovary: Chronic Fatigue, Quality of Life and Late Effects of Chemotherapy

Health Status and Burden of Late Effects in Very Long-term Testicular Cancer Survivors (STANDBY-study)

Swiss Austrian German Testicular Cancer Cohort Study - SAG TCCS

Therapy De-escalation in Seminoma Stage IIA/B

Survey of Testosterone Levels in Male Cancer Patients

Najkompletnija baza ljekovitog bilja potpomognuta znanošću